Barclays’s Aceragen Inc ACGN Stock Holding History

Barclays’s Portfolio ACGN Stock Details ACGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-1,766	Closed	-$480K	–	7688
2014 Q3	$480K	Hold	1,766	–	–	﹤0.01%	3987
2014 Q2	$480K	Buy	+1,766	New	+$728K	﹤0.01%	4026

Other funds holding ACGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

HCM

Hollencrest Capital Management Newport Beach, California $2.7B AUM 23.62% 1-Year Est. Return

Barclays's ACGN Position: Q2 2021 in Review

Barclays sold out of Aceragen Inc (ACGN) in Q2 2021, closing a stake of 730 shares — an estimated $16K sold.

Barclays first reported a position in ACGN in Q1 2014 and held it in 19 quarters. The position peaked at $821K in Q1 2018. 47 funds tracked by Wall St. Rank hold ACGN as of Q2 2021.

Barclays reported no remaining Aceragen Inc position as of Q2 2021 after selling out during the quarter.
Barclays sold 730 Aceragen Inc shares in Q2 2021, an estimated $16K.
Barclays first reported a position in Aceragen Inc in Q1 2014 and held it in 19 quarters.
Barclays's Aceragen Inc position peaked at $821K in Q1 2018.
47 funds tracked by Wall St. Rank held Aceragen Inc as of Q2 2021.

Based on Barclays's 13F filing for Q2 2021, filed 13 Aug 2021.